Arm CEO Rene Haas stated that the current chip shortage is hindering the development of AI in cancer treatment, such as modeling DNA markers affected by cancer, which remains too complex. However, he believes that as AI models and computers continue to evolve, AI will eventually solve the cancer problem. Haas also believes that concerns about a pullback in AI company stock prices are exaggerated, given the strong long-term demand for AI.